Plasma Homocystein elevelsin subjects with Deep Vein Thrombosis (DVT) and non- DVT

Mehdi Zobeiri, Alireza Hajiabadi, Mansour Rezaei

Abstract


Background: More recently, hyperhomocysteinemia was considered potentially as a reversible risk factor for venous thromboembolism. Mild hyperhomocysteinemia occurs in approximately 5 to 7 percent of the general population. This study investigates the plasma homocysteine concentration of patients with and without deep venous thrombosis.

Methods: This descriptive case -control study was done on 50 consecutive hospitalised patients with DVT and 50 individuals without DVT. Both groups were equalized with regards to factors such as age, sex, body mass index. The DVT of subjects was diagnosed by Doppler Sonography. Then theirfasting plasma homocysteine was measured.

Results: The mean level of homocysteine in patient and control groups were (20.48 ± 10.30, 18.06±7.67 μmol ∕ lit) respectively which have no statistically significant difference. (p=0.185). Eight % of patients had plasma homocysteine levels above the 95th percentile for the controls, as compared with 4% of the controls with a matched odds ratio of 2.09; 95 % CI: 0.365–11.95. The mean level of plasma homocysteine in individuals with HTN (23.21±10.42) were higher than the others (p<0.05).

Conclusion: The mean plasma homocysteine​ ​in both groups was above the normal range, but unlike other studies, there was no difference between them. On the other hand, lower homocysteine​​levels in pregnant women who used vitamin supplements (folate) suggest possible cofactor vitamins deficiency at the community level.

 


References


Di Micco P, Niglio A, De Renzo A, Lucania A, Di Fiore R, Scudiero O, et al. Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report. J Transl Med. 2004; 2(1): 7.

Perna AF, Castaldo P, Ingrosso D, De santo NG. Homocysteine, a new cardio vascular risk factor, is also a powerful uremic toxin. J Nephrol. 1999; 12(4): 230-40.

Stio F, Guerriero G, Ferri S, Iachetta RP, Scona M, Stio RE, et al. [Hyperhomocysteinemia and thrombosis: clinical case and literature's review (Italian)]. G Chir. 2002; 23(10): 372-5.

Wuillemin WA, Solenthaler M. [Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis (German)].Vasa. 1999; 28(3): 151-5.

Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006; 4:15.

Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44(2): 62–9.

den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996; 334(12): 759-62.

Ray JG. Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism. Curr Opin Pulm Med. 2008; 14(5): 369-73

Dalmau SJ, Ferrer LB, Modesto AV, Guillen DM, Vazquez GR, et al. Total plasma homocysteine levels. Relationship with plasmatic folic acid levels and 677C T polymorphism of 5, 10-methylenetetrahydrofolate reductase. An Esp Pediatr. 2002; 56(5): 399-401.

Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, et al. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost. 1996; 76(6):883-6.

Hoţoleanu C, Porojan-Iuga M, Rusu ML, Andercou A. Hyperhomocysteinemia:clinical and therapeutical involement in venous thrombosis. Rom J Intern Med. 2007; 45(2):159-64.

Karpati I, Balla J, Szoke G, Bereczky Z, Pall D, et al. Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation. Orv Hetil. 2002 7; 143(27): 1635-40.

Vinukonda G, Shaik Mohammad N, Md Nurul Jain J, Prasad Chintakindi K, Rama Devi Akella R. Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians. Clin Chim Acta. 2009; 405(1-2): 127-131.




DOI: http://dx.doi.org/10.22110/jkums.v16i4.671

Refbacks

  • There are currently no refbacks.


Copyright (c)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.